Table 1. Detection of Residual Disease... | American Society of Hematology

Table 1.

Detection of Residual Disease in CML Patients After SCT

Study	N	Test	Sensitivity	PCR⁺		PCR⁻
Study	N	Test	Sensitivity	Relapse	Remission	Relapse	Remission
Roth et al²⁰	64^*	Nested PCR	NA	10/31	21/31	0/23	23/23
Miyamura et al¹⁹	64	Nested PCR	1:10⁶	9/53	44/53	1/11	10/11
Hughes et al¹⁷	37	Nested PCR	1:10⁵	4/9	13/26	0/9	18/31
Radich et al¹⁸	346	Nested PCR	1:10⁶	33/117^†	84/117^†	14/319^†	303/319^†
Lin et al²²	98	Competitive PCR	50 transcripts/μg RNA	21/29^‡	8/29^‡	1/69^‡	68/69^‡
Gaiger et al²¹	30	Nested PCR	NA	5/15	10/15	0/15	15/15

Study	N	Test	Sensitivity	PCR⁺		PCR⁻
Study	N	Test	Sensitivity	Relapse	Remission	Relapse	Remission
Roth et al²⁰	64^*	Nested PCR	NA	10/31	21/31	0/23	23/23
Miyamura et al¹⁹	64	Nested PCR	1:10⁶	9/53	44/53	1/11	10/11
Hughes et al¹⁷	37	Nested PCR	1:10⁵	4/9	13/26	0/9	18/31
Radich et al¹⁸	346	Nested PCR	1:10⁶	33/117^†	84/117^†	14/319^†	303/319^†
Lin et al²²	98	Competitive PCR	50 transcripts/μg RNA	21/29^‡	8/29^‡	1/69^‡	68/69^‡
Gaiger et al²¹	30	Nested PCR	NA	5/15	10/15	0/15	15/15

Abbreviation: NA, not available.

Only 54 patients were studied at 2 or more time points.

†

Relapse data for 3 months and 6 to 12 months posttransplantation are based on Kaplan-Meier estimates.

‡

PCR⁺ indicates increasing or persistently highBCR-ABL transcript levels (>50 transcripts/μg RNA); PCR⁻ indicates undetectable, decreasing, or lowBCR-ABL transcript levels (<50 transcripts/μg RNA).

View Large

This Feature Is Available To Subscribers Only